Log in

Codiak BioSciences Stock Forecast, Price & News

+2.01 (+13.02 %)
(As of 12/4/2020 12:00 AM ET)
Today's Range
Now: $17.45
50-Day Range N/A
52-Week Range
Now: $17.45
Volume272,798 shs
Average Volume276,511 shs
Market Capitalization$327.50 million
P/E RatioN/A
Dividend YieldN/A
Codiak BioSciences, Inc. is harnessing exosomesÂnatural intercellular messengersÂto pioneer a new class of biologic medicines, exosome therapeutics. It develops the engEx Platform, versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutics. The company's two lead engEx product candidates, exoSTING and exoIL-12. Its engEx Platform has the potential to produce a broad pipeline of product candidates for the treatment of diseases with high unmet medical need, including in the areas of oncology, immune-based diseases, metabolic and fibrotic disorders, neurodegenerative disorders, and rare diseases. Codiak BioSciences, Inc. has a strategic collaboration with the Ragon Institute of MGH, MIT and Harvard to investigate the potential of exoVACC vaccine platform for SARS-CoV-2 and human immunodeficiency virus. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.83 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:CDAK
Phone617 949 4100



Sales & Book Value

Annual SalesN/A
Book Value($14.34) per share



Market Cap$327.50 million
Next Earnings Date2/18/2021 (Estimated)
OptionableNot Optionable
+2.01 (+13.02 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CDAK News and Ratings via Email

Sign-up to receive the latest news and ratings for CDAK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Codiak BioSciences (NASDAQ:CDAK) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Codiak BioSciences?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codiak BioSciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Codiak BioSciences
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Codiak BioSciences?

Wall Street analysts have given Codiak BioSciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Codiak BioSciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Codiak BioSciences' next earnings date?

Codiak BioSciences is scheduled to release its next quarterly earnings announcement on Thursday, February 18th 2021.
View our earnings forecast for Codiak BioSciences

What price target have analysts set for CDAK?

3 Wall Street analysts have issued 12 month price targets for Codiak BioSciences' stock. Their forecasts range from $19.00 to $29.00. On average, they anticipate Codiak BioSciences' stock price to reach $24.00 in the next twelve months. This suggests a possible upside of 37.5% from the stock's current price.
View analysts' price targets for Codiak BioSciences

Who are some of Codiak BioSciences' key competitors?

Who are Codiak BioSciences' key executives?

Codiak BioSciences' management team includes the following people:
  • Dr. Douglas Edward Williams, Pres, CEO & Director (Age 62, Pay $864.57k)
  • Dr. Eric S. Lander, Co-Founder & Independent Director (Age 63, Pay $32k)
  • Dr. Raghu Kalluri Ph.D., Co-Founder
  • Ms. Linda Cathavina Bain CPA, CPA, Chief Financial Officer (Age 50, Pay $516.88k)
  • Dr. Ajay Verma M.D., Ph.D., Exec. VP of Research & Experimental Medicine (Age 58, Pay $378.94k)
  • Prof. Jan Lotvall M.D., Ph.D., Chief Scientist
  • Kate Niazi-Sai, VP of Investor Relations & Communications
  • Ms. Yalonda Howze, Exec. VP, Chief Legal Officer & Corp. Sec. (Age 48)
  • Ms. Nicole Barna, Sr. VP of HR (Age 46)
  • Dr. Konstantin Konstantinov, Exec. VP of Manufacturing & Process Devel. (Age 62)

When did Codiak BioSciences IPO?

(CDAK) raised $82 million in an initial public offering on Wednesday, October 14th 2020. The company issued 5,500,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Evercore ISI, William Blair and Wedbush PacGrow served as the underwriters for the IPO.

What is Codiak BioSciences' stock symbol?

Codiak BioSciences trades on the NASDAQ under the ticker symbol "CDAK."

When did Codiak BioSciences' quiet period expire?

Codiak BioSciences' quiet period expired on Monday, November 23rd. Codiak BioSciences had issued 5,500,000 shares in its public offering on October 14th. The total size of the offering was $82,500,000 based on an initial share price of $15.00. During Codiak BioSciences' quiet period, insiders and any underwriters that worked on the IPO were prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Codiak BioSciences?

Shares of CDAK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Codiak BioSciences' stock price today?

One share of CDAK stock can currently be purchased for approximately $17.45.

How big of a company is Codiak BioSciences?

Codiak BioSciences has a market capitalization of $327.50 million. Codiak BioSciences employs 101 workers across the globe.

What is Codiak BioSciences' official website?

The official website for Codiak BioSciences is www.codiakbio.com.

How can I contact Codiak BioSciences?

The company can be reached via phone at 617 949 4100 or via email at [email protected]

This page was last updated on 12/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.